Intas Pharmaceuticals has launched its first biosimilar product, Accofil, used in treating immune system disorders, in European markets.
The company has launched its first biosimilar, filgrastim, in Europe through its wholly-owned subsidiary Accord Healthcare, Intas Pharmaceuticals said in a statement.
The product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK, it added.
"In addition, Intas is also the only company from India to have two of its products, filgrastim and peg-filgrastim, filed for registration in the US, through its collaboration partner," the company said.
Accofil is indicated for the treatment of reduction in the duration of neutropenia and the incidence of febrile neutropenia.
"The launch of our filgrastim in Europe is another demonstration of our commitment to global healthcare at affordable prices," Intas Pharmaceuticals Vice Chairman Binish Chudgar said.
This is only the first of many biological products that the company will launch in European Union and other regulated markets over next few years, he added.
